In this issue:
JAVELIN head and neck 100 terminated - avelumab added to CRT does not extend PFS
Durable three-year responses to front-line pembrolizumab in MCC
Vismodegib for basal cell carcinoma
Histologic regression of stage 1/2 melanoma may be prognostic for favourable outcome
Treatment of early-stage mycosis fungoides
Biopsy outperforms RCM in diagnosing and subtyping BCC
Inferior survival in nodular versus superficial spreading melanomas
Increased risk for SCC and BCC with hydrochlorothiazide
Histopathologic scoring system for PNI predicts adverse outcomes in cutaneous SCC
Willingness to pay for surgical treatments for BCC
Please login below to download this issue (PDF)